Rigel Pharmaceuticals (RIGL) Accumulated Expenses (2010 - 2026)

Rigel Pharmaceuticals' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $6.0 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses changed 0.25% year-over-year to $6.0 million in Q1 2026; TTM through Mar 2026 was $6.0 million, a 0.25% change from a year earlier, with the FY2025 full-year figure at $11.9 million, up 17.51% from the prior year.
• Accumulated Expenses retreated to $6.0 million in Q1 2026 per RIGL's latest filing, from $11.9 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $11.9 million in Q4 2025 and bottomed at $5.2 million in Q1 2024.
• The 5-year median for Accumulated Expenses is $7.9 million (2025), against an average of $7.8 million.
• Across the five-year window, Accumulated Expenses fell 17.06% in 2022 and climbed 27.02% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $8.9 million in 2022, then decreased by 2.14% to $8.7 million in 2023, then increased by 16.86% to $10.1 million in 2024, then grew by 17.51% to $11.9 million in 2025, then plunged by 49.56% to $6.0 million in 2026.
• Per Business Quant, the three latest RIGL Accumulated Expenses figures stand at $6.0 million (Q1 2026), $11.9 million (Q4 2025), and $10.1 million (Q3 2025).